Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?

Company Performance - Aurinia Pharmaceuticals (AUPH) has returned approximately 81.2% since the start of the calendar year, significantly outperforming the average gain of 8.2% for Medical stocks [4] - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [4] - Aurinia Pharmaceuticals is currently ranked 2 (Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [3] Industry Comparison - Aurinia Pharmaceuticals is part of the Medical - Drugs industry, which includes 146 stocks and is currently ranked 70 in the Zacks Industry Rank, with an average gain of 9.4% this year [6] - In contrast, Cardinal Health (CAH), another Medical stock, has returned 75.5% since the beginning of the year and is part of the Medical - Dental Supplies industry, which is ranked 102 and has gained 13.3% [5][6] - The Medical group, which includes Aurinia Pharmaceuticals, is currently ranked 6 within the Zacks Sector Rank, which evaluates 16 different sector groups [2]